COMP <GO>
LGND vs UNH // FREE CASH FLOW YIELD
Ligand Pharmaceuticals Incorporated (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: LGND 7
— UNH 8
▲ FREE CASH FLOW YIELD LEADER: UNH
LAST: $322.75 (+1.71%) • MKT CAP: $6.33B
fcf-yield
0.77%
LAST: $406.97 (-0.96%) • MKT CAP: $364.66B
fcf-yield
6.48%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LGND VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | LGND | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 88.57% | -47.57 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 3.00% | 11.47% | -8.47 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | 95.0x | 16.4x | +78.55 | UNH | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | 0.77% | 6.48% | -5.71 | UNH | /fcf-yield <GO> |
| Operating Margin | 15.30% | 4.82% | +10.48 | LGND | /operating-margins <GO> |
| Net Profit Margin | 46.40% | 3.14% | +43.26 | LGND | /net-margins <GO> |
| Revenue Growth (YoY) | 60.40% | 6.46% | +53.94 | LGND | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 8.40 | 3.12 | +5.28 | LGND | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | LGND | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.10% | 6.74% | +0.36 | UNH | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 63.4 | 56.0 | +7.34 | LGND | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.07 | 0.33 | +0.74 | LGND | /macro-sensitivity <GO> |
| Forward P/E Multiple | 42.7x | 17.1x | +25.61 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $6.33B | $364.66B | -$358.33B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | LGND REV | UNH REV | LGND GROSS % | UNH GROSS % | LGND FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $268.1M | $447.57B | 44.0% | 88.7% | $48.9M | $16.07B |
| FY 2024 | $167.1M | $400.28B | 44.0% | 88.3% | $95.2M | $20.70B |
| FY 2023 | $131.3M | $371.62B | 44.0% | 89.6% | $43.7M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LGND // BETA 1.07
UNH // BETA 0.33